evocalcet

11/01/2023 - "Evocalcet is an oral calcimimetic agent with proven efficacy and safety in treating secondary hyperparathyroidism (SHPT) in Japanese patients on dialysis. "
11/01/2023 - "Evocalcet Rescues Secondary Hyperparathyroidism-driven Cortical Porosity in CKD Male Rats."
05/30/2022 - "Evocalcet is a calcimimetic for the treatment of secondary hyperparathyroidism. "
11/01/2021 - "Evocalcet is a recently approved calcimimetic agent for secondary hyperparathyroidism (SHPT). "
06/01/2020 - "Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism."

09/01/2020 - "We conducted an open-label, single-arm, 52-week, phase III study in Japanese patients with hypercalcemia due to PHPT to demonstrate efficacy and safety of evocalcet, a new calcimimetic. "
01/05/2023 - "Evocalcet, which is used to treat hypercalcemia due to PHPT, does not interact with P450 (CYP) and causes few side effects. "
01/05/2023 - "The mass was suspected as PC because the hypercalcemia was refractory to high-dose evocalcet. "
01/05/2023 - "Here, we report a case of PC with remarkably persistent hypercalcemia, which we safely and quickly controlled with rapidly increasing evocalcet doses. "
01/05/2023 - "Hypercalcemia due to parathyroid carcinoma (PC) is safely and quickly controlled with rapidly increasing evocalcet doses. "

09/01/2020 - "Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study."

01/01/2020 - "We observed the effects of evocalcet on ectopic calcification and parathyroid hyperplasia using chronic kidney disease (CKD) rats with SHPT. "
10/01/2018 - "Evocalcet is a novel calcimimetic agent with potential to improve the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. "
11/13/2020 - "Efficacy and safety of evocalcet in treatment of secondary hyperparathyroidism in chronic kidney disease on hemodialysis patients: A protocol for a systematic review and meta-analysis."
11/01/2023 - "To elucidate the effect of evocalcet, a new oral calcimimetic to bone of secondary hyperparathyroidism (SHPT) with chronic kidney disease (CKD), the rats were 5/6 nephrectomized and fed on a high-phosphate diet. "
10/01/2018 - "These results suggest that evocalcet may have a comparable efficacy and better safety profile than that of cinacalcet, one of the current treatments for secondary hyperparathyroidism in patients with chronic kidney disease."

01/05/2023 - "Hypercalcemia due to parathyroid carcinoma (PC) is safely and quickly controlled with rapidly increasing evocalcet doses. "
01/05/2023 - "Effect of early dose increase of evocalcet for intractable hypercalcemia caused by parathyroid carcinoma."
11/15/2022 - "Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma."
01/05/2023 - "General therapy for hypercalcaemia including aggressive saline dehydration, administration of furosemide, calcitonin, zoledronic acid, and evocalcet, and dialysis is sometimes ineffective for parathyroid carcinoma. "